Metagenomi Therapeutics (MGX) Other Non-Current Assets (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Other Non-Current Assets of $4.4 million for Q1 2026, down 16.29% year-over-year from $5.2 million in Q1 2025, and down 15.41% quarter-over-quarter from $5.2 million in Q4 2025.
Metagenomi Therapeutics (MGX) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Other Non-Current Assets for 4 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 16.29% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (down 16.29% YoY), while the FY2025 annual figure was $5.2 million, up 1709.41% from the prior year.
- Other Non-Current Assets retreated to $4.4 million in Q1 2026 per MGX's latest filing, from $5.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $6.1 million in Q1 2023 and bottomed at $287000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $4.5 million across 4 years, with a median of $5.2 million in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets slumped 94.53% — and 2025, when it jumped 1709.41%.
- Metagenomi Therapeutics' Other Non-Current Assets stood at $5.2 million in 2023, then plunged by 94.53% to $287000.0 in 2024, then surged by 1709.41% to $5.2 million in 2025, then decreased by 15.41% to $4.4 million in 2026.
- Business Quant data shows MGX's Other Non-Current Assets at $4.4 million in Q1 2026, $5.2 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 4.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.39 Mn |
| Mar 31, 2026 | 4.39 Mn |
| Dec 31, 2025 | 5.19 Mn |
| Sep 30, 2025 | 5.25 Mn |
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 5.25 Mn |
| Dec 31, 2024 | 287,000.00 |
| Sep 30, 2024 | 5.25 Mn |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 5.25 Mn |
| Dec 31, 2023 | 5.25 Mn |
| Sep 30, 2023 | 5.25 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 6.07 Mn |